Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
Recruiting now · Phase 4
Conditions studied: Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
In brief
Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg. This trial aims to prove non-inferiority of concomitant usage of low dose rosuvastatin and ezetimibe among patients with acute myocardial infarction who went through percutaneous coronary intervention at decreasing major adverse cardiac events compared to the efficacy of single use of high dose rosuvastatin.
Key facts
- Study ID
- NCT04499859
- Run by
- Kiyuk Chang, MD,PhD
- People needed
- 3548
- Starts
- 2020-10-01
- Expected to finish
- 2027-08-30
- Last updated by the study team
- 2025-07-30
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults Aged 19 and up
- Patients diagnosed with myocardial infarction (both ST segment elevation and non-ST segment elevation) who were treated with percutaneous coronary intervention (Myocardial infarction defined as in the 4th Universal Definition of Myocardial Infarction)
- For female patients who are of childbearing age, subjects that agreed on taking mandatory pregnancy test
- Patients who agreed and signed on the informed consent form
You may not qualify if…
- Patients with life expectancy of a year or less due to malignancy
- Patients with chronic liver disease
- Patients with sensitivity to active ingredient of the research drugs (ezetimibe and/or rosuvastatin) or patients who are prohibited to take ezetimibe and/or rosuvastatin.
- Pregnant and/or breastfeeding
- Female patients who are unable to use any means of contraception
- Patients receiving hemodialysis, peritoneal dialysis patients and/or kidney transplant patients, due to end stage renal disease
- Patients who participated in other clinical trial(s) within 3 months from the screening (except non-interventional observational study)
- Patients considered inappropriate for the study for any other reason(s) by the inspector(s)
Where it is running
- Bucheon St.Mary Hospital — Bucheon-si, Gyeonggido, South Korea (enrolling)
- St.Vincent's Hospital — Suwon, Gyeonggido, South Korea (enrolling)
- Uijeongbu St.Mary's Hospital — Uijeongbu-si, Gyeonggido, South Korea (enrolling)
- Daejeon St.Mary's Hospital — Daejeon, South Korea (enrolling)
- Incheon St.Mary's Hospital — Incheon, South Korea (enrolling)
- Seoul St.Mary's Hospital — Seoul, South Korea (enrolling)
- Yeouido St.Mary Hospital — Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.